Inventor · disambiguated record
Korden Walter
Also filed as: WALTER KORDEN
18 granted patents·9 pending applications·66 citations·filing 2010–2024
92Inventor score
Files withGANYMED PHARMACEUTICALS GMBH9GANYMED PHARMACEUTICALS AG8SAHIN UGUR4ASTELLAS PHARMA INC3BIONTECH AG3
Top patents by PatentIndex Score
27 records- 0193US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 0293US9718886B2Cancer therapy using CLDN6 target-directed antibodies in vivoSAHIN UGUR·Filed 2011·Granted Aug 1, 2017·13 cites·6 claims
- 0392US9487584B2Antibodies specific for claudin 6 (CLDN6)SAHIN UGUR·Filed 2010·Granted Nov 8, 2016·19 cites·20 claims
- 0492US9321842B2Antibodies for treatment of cancerSAHIN UGUR·Filed 2012·Granted Apr 26, 2016·14 cites·30 claims
- 0590US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 0686US10604568B2Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2014·Granted Mar 31, 2020·6 cites·10 claims
- 0785US2024092896A1Antibodies specific for claudin 6 (cldn6)GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 0884US11473085B2Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2019·Granted Oct 18, 2022·1 cites·10 claims
- 0984US2024101703A1Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1083US2024209079A1Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 1183US2024084033A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1280US11541127B2Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 3, 2023·2 cites·28 claims
- 1378US11919951B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2022·Granted Mar 5, 2024·0 cites·21 claims
- 1478US2024059772A1Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2023·Application pending·0 cites
- 1577US9902778B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Feb 27, 2018·1 cites·19 claims
- 1677US2023193261A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1775US9932401B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Apr 3, 2018·1 cites·19 claims
- 1871US11858988B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·24 claims
- 1970US2023270878A1Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2069US2021079113A1Cancer therapy using cldn6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 2168US11279757B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2018·Granted Mar 22, 2022·0 cites·20 claims
- 2268US10919974B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Feb 16, 2021·0 cites·12 claims
- 2367US11795218B2Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2020·Granted Oct 24, 2023·0 cites·22 claims
- 2466US10745477B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Aug 18, 2020·0 cites·19 claims
- 2564US10844133B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Nov 24, 2020·0 cites·20 claims
- 2656US2018119146A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 2750US9809815B2Methods and compositions for diagnosis and treatment of cancerSAHIN UGUR·Filed 2010·Granted Nov 7, 2017·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →